Recurrent Melanoma Completed Phase 2 Trials for Tipifarnib (DB04960)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00060125Tipifarnib in Treating Patients With Metastatic Malignant MelanomaTreatment
NCT00281957Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By SurgeryTreatment